Zencore Biologics provides custom media formulations tailored for client's specific CHO-based applications based on our experienced media development platform. We offer a broad portfolio of CHO media formulations for production of therapeutics in different modalities, including perfusion culture, fed-batch culture, and cell line development. The media manufactured by Zencore have been proven to be robust and high productivity. On Average, our custom-made media has shown to have a therapeutic production throughput of more than 5g/L and as high as 15g/L.
Highly flexible, culture media can be tailored to any specific cell line
Easily controlled and definite composition, avoide the short-comings of commercial media
Rapid response, we incorporate science-driven design technology into our media formulations and simplify upstream workflows
Media formulation development
Media formulation optimization
Media pilot production in liquid or dry powder form
Cell line from client will be thawed for creating an adaptive culture and establishing a working cell line. The existing formulation and culture process will be evaluated via fed-batch (shaker flask, and bioreactor if necessary) for reproducibility.
A comprehensive quality testing process will be established and validated according to your transferred testing procedures or Zencore QC analysis platform.
The media and supplements will be determined based on their ability to support optimal process characteristics.
MVA will give support to the further formulation optimization for identifying the key nutritional components that will impact protein yield and quality.
Utilizing our platform high throughput analysis, we will be able to monitor nutrients and metabolism in CHO-based cell line. This approach enables us to optimize the regulation of cell metabolism and the reduction of by-products generated.
The correlation between key components in the media formulation and product titer will be evaluated. This enables us to further improve the output of the target protein by the optimization of the ratio of key components in the media formulation. Development, testing and manufacturing are performed at Zencore facilities, and improvement could be delivered in a shorter time than other competitors.
Once a media formulation is identified using our media platform, the cells will be grown in 2L-5L bioreactor to verify the formulation. This will enable us to further optimize cell growth, process characteristics, cellular metabolism, product yield and quality attributes.
Based on the optimized liquid formulation, the dry media powder will be developed. The process characteristics of dry powder media products will be further confirmed using a larger bioreactor (≤ 20L) to ensure the pre-defined performance criteria of dry-powder media is no less than 80% of the liquid form.
The original client product was underperforming with increased oxidation and truncation,Zencore Biologics redeveloped the promising media and optimized the cell culture & purification process to match the quality of a biosimilar that was developed by our client.Zencore Biologics will provide proprietary media to meet your higher quality standards.
Zencore Biologics has helped a client improve the quality attributes of a biosimilar to be highly consistent with the original molecule via media screening and formulation optimization, which accelerated phase III clinical trials.
Increased mAb Antibody Titer Using A Custom Media Formulation
Zencore media development team successfully increased the titer for an innovative monoclonal antibody to over 9.6g/L using our custom media. Compared with mainstream commercial media, the media developed by Zencore had better performance for cell culture.
Zencore media development team successfully increased the titer for an innovative monoclonal antibody to over 9.6g/L using our custom media. Compared with mainstream commercial media,the media developed by Zencore had better performance for cell culture.
Zencore Biologics provides multiple proprietary media combinations with various nutrient formulations for CHO-based processes and can be customized for your specific needs. Using our high throughput platform, we will help you find the appropriate media formulation for selecting your primary clone and optimization, while improving the titer suitable for manufacturing. We are supporting our clients' tight timelines on a case by case basis.
As shown below, three proprietary media by Zencore supported four different cell lines for 7.1 -10.5g/L production at the stage of clone selection and evaluation.
